Privi Speciality Chemicals Receives No Objection from NSE on Amalgamation Scheme
Privi Speciality Chemicals Limited provided an update on the proposed scheme of amalgamation involving the company and two other entities. The scheme involves Privi Speciality Chemicals Limited and its merger with Privi Fine Sciences Private Limited and Privi Biotechnologies Private Limited.The update addresses the initial board approval given by the company’s directors for the proposed amalgamation scheme, which occurred following a previous intimation on December 19, 2025.
Privi Speciality Chemicals Limited announced that the company has received an observation letter with no objection from the National Stock Exchange of India Limited. This observation letter from NSE was dated May 05, 2026. The company noted that the observation letter from the Bombay Stock Exchange (BSE) remains awaited.
The amalgamation scheme involves:
- Target Company: Privi Speciality Chemicals Limited
- Transferor Company 1: Privi Fine Sciences Private Limited
- Transferor Company 2: Privi Biotechnologies Private Limited
PRIVISCL Stock Price Movement
Shares of Privi Speciality Chemicals Limited are shedding ₹17.60, or 0.52%, as of 1:31 PM today, trading at ₹3357.6. The stock shows recent momentum in live trading, with 20,276 shares transacting to reflect the day's movement.Disclaimer: Due care and diligence have been taken in compiling and presenting news and market-related content. However, errors or omissions may arise despite such efforts.
The information provided is for general informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any securities. Readers are advised to rely on their own assessment and judgment and consult appropriate financial advisers, if required, before taking any investment-related decisions.
Any views, opinions, or statements expressed, where applicable, are those of the respective analysts or experts and do not reflect the views of this website. The website has no association with such viewpoints and does not assume any responsibility for them.